secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2022-09-30T23:59:59+00:00
Accession:  0001193125-22-255495
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences to acquire AavantiBio; announces $75M private placement
-------------------------------------------------------------------------

- Merger: Solid acquires AavantiBio through transitory subsidiary merger; AavantiBio survives as wholly owned.
- Private placement of 159,574,463 shares at $0.47/share for ~$75M from accredited investors.
- Closing requires stockholder approval; private placement closes immediately after merger.
- Combined pipeline includes SGT-003 for Duchenne, AVB-202 for Friedreich's ataxia, AVB-401 for BAG3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522255495/0001193125-22-255495-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522255495/d391920d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-255495

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer